The Young Adult and Pediatric Bipolar Study

NCT ID: NCT00350857

Last Updated: 2014-02-20

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

161 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-07-31

Study Completion Date

2007-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To examine the safety and effectiveness of extended-release carbamazepine in the treatment of children and adolescents aged 10-17 years with acute manic or mixed bipolar I disorder.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bipolar I Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Equetro active

Group Type ACTIVE_COMPARATOR

Extended-Release Carbamazepine

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Extended-Release Carbamazepine

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. DSM-IV diagnosis of bipolar I disorder, most recent episode manic or mixed.
2. A lifetime history of bipolar disorder symptoms for at least 2 months.
3. YMRS score greater than or equal to 16.
4. CGI-S score greater than or equal to 4.
5. Male or female outpatient aged between 10-17 years old inclusive at the time of consent.
6. Functioning at an age-appropriate level intellectually, as deemed by the Investigator.
7. The subject has no co-morbid illness that could affect efficacy, safety, or tolerability or in any way interfere with the subject's participation in the study.
8. Must have a satisfactory medical assessment with no clinically significant and relevant abnormalities.

Exclusion Criteria

1. Current controlled or uncontrolled, co-morbid psychiatric diagnosis that could interfere with clinical assessments or study conduct.
2. A history of lack of therapeutic response or hypersensitivity to the study drug.
3. A greater than or equal to 50% reduction in YMRS between Screening and Baseline.
4. Acutely at risk for suicidal or violent behavior or a history of suicide attempts requiring medical intervention.
5. A history of aplastic anemia, agranulocytosis or bone marrow depression.
6. A history of seizure disorder, other than a single childhood febrile seizure.
7. A history of severe, unstable asthma.
8. Current hospitalization for psychiatric symptoms.
9. History of alcohol or other substance abuse or dependence.
10. Pregnant or lactating females.
11. Body weight less than or equal to 25 kg.
Minimum Eligible Age

10 Years

Maximum Eligible Age

17 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Validus Pharmaceuticals

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

11 Shire Clinical Research Site

Altamonte Springs, Florida, United States

Site Status

17 Segal Institute for Clinical Research

Fort Lauderdale, Florida, United States

Site Status

19 Sarkis Clinical Trials

Gainesville, Florida, United States

Site Status

23 Shire Clinical Research Site

Jacksonville, Florida, United States

Site Status

21 Scientific Clinical Research

North Miami, Florida, United States

Site Status

14 Northlake Medical Research

Decatur, Georgia, United States

Site Status

04 Mountain West Clinical Trials

Eagle, Idaho, United States

Site Status

25 Capstone Clinical Research

Libertyville, Illinois, United States

Site Status

15 Psychiatric Associates

Overland Park, Kansas, United States

Site Status

27 Owensboro Behavioral Care

Owensboro, Kentucky, United States

Site Status

05 Brentwood Research Institute

Shreveport, Louisiana, United States

Site Status

13 Pharmasite Research, Inc

Baltimore, Maryland, United States

Site Status

02 Finger Lakes Clinical Research

Rochester, New York, United States

Site Status

01 Nccacrf

Chapel Hill, North Carolina, United States

Site Status

06 University of Cincinnati, College of Medicine

Cincinnati, Ohio, United States

Site Status

09 Discovery and Wellness Center for Children

Cleveland, Ohio, United States

Site Status

03 IPS Research

Oklahoma City, Oklahoma, United States

Site Status

26 Suburban Research Associates

Media, Pennsylvania, United States

Site Status

12 Claghorn-Lesem Research Clinic

Bellaire, Texas, United States

Site Status

07 Center for Pediatric Psychiatry

Dallas, Texas, United States

Site Status

24 Red Oak Psychiatry Associates

Houston, Texas, United States

Site Status

10 RID Clinical Research, Inc

Lake Jackson, Texas, United States

Site Status

08 Dominion Clinical Research

Midlothian, Virginia, United States

Site Status

22 Brighton Research Group

Virginia Beach, Virginia, United States

Site Status

20 Shire Clinical Research Site

Milwaukee, Wisconsin, United States

Site Status

16 Rogers Center for Research and Training

Milwaukee, Wisconsin, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SPD417-311

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.